載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$0.8789
+US$0.0202 · +2.35%
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
前收盤價
US$0.8789
+US$0.0202 · +2.35%
盤中時間採用ET。市場資料可能有所延遲。
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
日內區間
目前US$0.8789
52週區間
目前US$0.8789
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
43
合理估值
情緒
59
多空交錯
風險
69
高風險
動能
19
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
日內區間
目前US$0.8789
52週區間
目前US$0.8789
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.7萬 USD | — | — | 8.6萬 USD | — |
| 銷貨成本 | 84.4萬 USD | 1.6萬 USD | 1.5萬 USD | 1.5萬 USD | 7000 USD |
| 毛利 | −82.7萬 USD | −1.6萬 USD | −1.5萬 USD | 7.1萬 USD | −7000 USD |
| 研究與開發 | 113.6萬 USD | 1170.5萬 USD | 603.5萬 USD | 442.2萬 USD | 286萬 USD |
| 銷售、一般及管理費用 | 302.4萬 USD | 295.2萬 USD | 354.9萬 USD | 444.7萬 USD | 434.8萬 USD |
| 營業費用 | 416萬 USD | 1465.7萬 USD | 958.4萬 USD | 886.9萬 USD | 720.8萬 USD |
| 利息收入 | 12萬 USD | 10.1萬 USD | 40.6萬 USD | 16萬 USD | — |
| 利息支出 | 1萬 USD | 1.4萬 USD | 38.4萬 USD | 6.1萬 USD | 1萬 USD |
| 折舊和攤銷 | 77.4萬 USD | 1.6萬 USD | 1.5萬 USD | 1.5萬 USD | 7000 USD |
| 營業利益 | −498.7萬 USD | −1467.3萬 USD | −958.4萬 USD | −886.9萬 USD | −720.8萬 USD |
| 淨利 | −483.8萬 USD | −1458.8萬 USD | −934.4萬 USD | −879.2萬 USD | −724.6萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
